

Ordering Provider	Collect Date & Time	Date of Service	Status Change Date	Status	Signed	Req. Number	
ROETHLE, S	4/1/2021 8:51 am	4/1/2021 12:00 am	4/20/2021 8:07pm	FINAL	04/21/2021 PEYTON	B0113848486	
Diagnostic Test / Results	Results	Out of Range	Flag	Units	Range	Site	Stat
<b>CBC With Differential/Platelet [Final]</b>							
Notes	Fasting - Yes						
WBC	5.7			x10E3/u L	3.4-10.8	01	F
RBC	5.65			x10E6/u L	4.14-5.80	01	F
Hemoglobin	16.3			g/dL	13.0-17.7	01	F
Hematocrit	49.9			%	37.5-51.0	01	F
MCV	88			fL	79-97	01	F
MCH	28.8			pg	26.6-33.0	01	F
MCHC	32.7			g/dL	31.5-35.7	01	F
RDW	14.2			%	11.6-15.4	01	F
Platelets	212			x10E3/u L	150-450	01	F
Neutrophils	50			%	Not Estab.	01	F
Lymphs	40			%	Not Estab.	01	F
Monocytes	7			%	Not Estab.	01	F
Eos	2			%	Not Estab.	01	F
Basos	1			%	Not Estab.	01	F
Immature Cells	NP					01	X
Neutrophils (Absolute)	2.9			x10E3/u L	1.4-7.0	01	F
Lymphs (Absolute)	2.3			x10E3/u L	0.7-3.1	01	F
Monocytes(Absolute)	0.4			x10E3/u L	0.1-0.9	01	F
Eos (Absolute)	0.1			x10E3/u L	0.0-0.4	01	F
Baso (Absolute)	0.0			x10E3/u L	0.0-0.2	01	F
Immature Granulocytes	0			%	Not Estab.	01	F
Immature Grans (Abs)	0.0			x10E3/u L	0.0-0.1	01	F
NRBC	NP					01	X
Hematology Comments:	NP					01	X
<b>Comp. Metabolic Panel (14) [Final]</b>							
Glucose	92			mg/dL	65-99	01	F
BUN	19			mg/dL	6-24	01	F
Creatinine	1.26			mg/dL	0.76-1.27	01	F
eGFR If NonAfricn Am	67			mL/min/1 .73	>59	01	F
eGFR If Africn Am	78			mL/min/1 .73	>59	01	F
BUN/Creatinine Ratio	15				9-20	01	F
Sodium	139			mmol/L	134-144	01	F
Potassium	5.1			mmol/L	3.5-5.2	01	F
Chloride	102			mmol/L	96-106	01	F
Carbon Dioxide, Total	24			mmol/L	20-29	01	F
Calcium	9.7			mg/dL	8.7-10.2	01	F
Protein, Total	7.4			g/dL	6.0-8.5	01	F
Albumin	4.6			g/dL	4.0-5.0	01	F
Globulin, Total	2.8			g/dL	1.5-4.5	01	F
A/G Ratio	1.6				1.2-2.2	01	F
Bilirubin, Total	0.8			mg/dL	0.0-1.2	01	F
<b>Flag Legend:</b> Flag Legend: L (Below Low Normal) H (Above High Normal) LL (Alert Low) HH (Alert High) < (Panic Low) > (Panic High) A (Abnormal) AA (Critical Abnormal)							
<b>Lab Patient Name:</b> ██████████		<b>DOB:</b> ████████		<b>SSN:</b> ████████		<b>Client:</b>	

Ordering Provider	Collect Date & Time	Date of Service	Status Change Date	Status	Signed	Req. Number																																																							
ROETHLE, S	4/1/2021 8:51 am	4/1/2021 12:00 am	4/20/2021 8:07pm	FINAL	04/21/2021 PEYTON	B0113848486																																																							
Diagnostic Test / Results	Results	Out of Range	Flag	Units	Range	Site	Stat																																																						
<b>Comp. Metabolic Panel (14) [Final]</b>																																																													
Alkaline Phosphatase	59			IU/L	39-117	01	F																																																						
AST (SGOT)	27			IU/L	0-40	01	F																																																						
ALT (SGPT)	24			IU/L	0-44	01	F																																																						
<b>Lipid Panel w/ Chol/HDL Ratio [Final]</b>																																																													
Cholesterol, Total		222	H	mg/dL	100-199	01	F																																																						
Triglycerides	119			mg/dL	0-149	01	F																																																						
HDL Cholesterol	53			mg/dL	>39	01	F																																																						
VLDL Cholesterol Cal	21			mg/dL	5-40	01	F																																																						
LDL Chol Calc (NIH)		148	H	mg/dL	0-99	01	F																																																						
Comment:	NP					01	X																																																						
T. Chol/HDL Ratio	4.2			ratio	0.0-5.0	01	F																																																						
Notes	<p>T. Chol/HDL Ratio</p> <table border="1"> <thead> <tr> <th></th> <th>Men</th> <th>Women</th> </tr> </thead> <tbody> <tr> <td>1/2 Avg.Risk</td> <td>3.4</td> <td>3.3</td> </tr> <tr> <td>Avg.Risk</td> <td>5.0</td> <td>4.4</td> </tr> <tr> <td>2X Avg.Risk</td> <td>9.6</td> <td>7.1</td> </tr> <tr> <td>3X Avg.Risk</td> <td>23.4</td> <td>11.0</td> </tr> </tbody> </table>								Men	Women	1/2 Avg.Risk	3.4	3.3	Avg.Risk	5.0	4.4	2X Avg.Risk	9.6	7.1	3X Avg.Risk	23.4	11.0																																							
	Men	Women																																																											
1/2 Avg.Risk	3.4	3.3																																																											
Avg.Risk	5.0	4.4																																																											
2X Avg.Risk	9.6	7.1																																																											
3X Avg.Risk	23.4	11.0																																																											
<b>Testosterone,Free and Total [Final]</b>																																																													
Testosterone, Serum	693			ng/dL	264-916	01	F																																																						
Notes	<p>Adult male reference interval is based on a population of healthy nonobese males (BMI &lt;30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.</p> <p><b>**Effective May 10, 2021 Testosterone, Serum**</b></p> <p>reference interval will be changing to:</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Male</th> <th>Female</th> </tr> </thead> <tbody> <tr><td>0 - 30 days</td><td>0 - 650</td><td>4 - 190</td></tr> <tr><td>1 - 5 months</td><td>0 - 650</td><td>0 - 42</td></tr> <tr><td>6 months</td><td>0 - 36</td><td>0 - 42</td></tr> <tr><td>7m- 1 year</td><td>0 - 36</td><td>1 - 26</td></tr> <tr><td>2 - 5 years</td><td>0 - 36</td><td>3 - 33</td></tr> <tr><td>6 - 8 years</td><td>0 - 36</td><td>3 - 25</td></tr> <tr><td>9 - 10 years</td><td>0 - 21</td><td>1 - 33</td></tr> <tr><td>11 years</td><td>1 - 161</td><td>5 - 58</td></tr> <tr><td>12 years</td><td>2 - 521</td><td>5 - 58</td></tr> <tr><td>13 - 15 years</td><td>28 - 656</td><td>12 - 71</td></tr> <tr><td>16 - 17 years</td><td>150 - 785</td><td>12 - 71</td></tr> <tr><td>18 - 19 years</td><td>150 - 785</td><td>13 - 71</td></tr> <tr><td>20 - 30 years</td><td>264 - 916</td><td>13 - 71</td></tr> <tr><td>31 - 40 years</td><td>264 - 916</td><td>8 - 60</td></tr> <tr><td>41 - 60 years</td><td>264 - 916</td><td>4 - 50</td></tr> <tr><td>61 - 80 years</td><td>264 - 916</td><td>3 - 67</td></tr> <tr><td>&gt;80 years</td><td>264 - 916</td><td>2 - 45</td></tr> </tbody> </table>							Age	Male	Female	0 - 30 days	0 - 650	4 - 190	1 - 5 months	0 - 650	0 - 42	6 months	0 - 36	0 - 42	7m- 1 year	0 - 36	1 - 26	2 - 5 years	0 - 36	3 - 33	6 - 8 years	0 - 36	3 - 25	9 - 10 years	0 - 21	1 - 33	11 years	1 - 161	5 - 58	12 years	2 - 521	5 - 58	13 - 15 years	28 - 656	12 - 71	16 - 17 years	150 - 785	12 - 71	18 - 19 years	150 - 785	13 - 71	20 - 30 years	264 - 916	13 - 71	31 - 40 years	264 - 916	8 - 60	41 - 60 years	264 - 916	4 - 50	61 - 80 years	264 - 916	3 - 67	>80 years	264 - 916	2 - 45
Age	Male	Female																																																											
0 - 30 days	0 - 650	4 - 190																																																											
1 - 5 months	0 - 650	0 - 42																																																											
6 months	0 - 36	0 - 42																																																											
7m- 1 year	0 - 36	1 - 26																																																											
2 - 5 years	0 - 36	3 - 33																																																											
6 - 8 years	0 - 36	3 - 25																																																											
9 - 10 years	0 - 21	1 - 33																																																											
11 years	1 - 161	5 - 58																																																											
12 years	2 - 521	5 - 58																																																											
13 - 15 years	28 - 656	12 - 71																																																											
16 - 17 years	150 - 785	12 - 71																																																											
18 - 19 years	150 - 785	13 - 71																																																											
20 - 30 years	264 - 916	13 - 71																																																											
31 - 40 years	264 - 916	8 - 60																																																											
41 - 60 years	264 - 916	4 - 50																																																											
61 - 80 years	264 - 916	3 - 67																																																											
>80 years	264 - 916	2 - 45																																																											
Free Testosterone(Direct)	8.2			pg/mL	6.8-21.5	02	F																																																						
<b>Hemoglobin A1c [Final]</b>																																																													
Hemoglobin A1c	5.6			%	4.8-5.6	01	F																																																						
Notes	<p>Prediabetes: 5.7 - 6.4 Diabetes: &gt;6.4 Glycemic control for adults with diabetes: &lt;7.0</p>																																																												
<b>DHEA-Sulfate [Final]</b>																																																													
DHEA-Sulfate	111.0			ug/dL	71.6-375.4	01	F																																																						
<b>TSH [Final]</b>																																																													
TSH	0.697			uIU/mL	0.450-4.500	01	F																																																						
<b>Luteinizing Hormone(LH), S [Final]</b>																																																													
<b>Flag Legend:</b> Flag Legend: L (Below Low Normal) H (Above High Normal) LL (Alert Low) HH (Alert High) < (Panic Low) > (Panic High) A (Abnormal) AA (Critical Abnormal)																																																													
<b>Lab Patient Name:</b> ██████████ <b>DOB:</b> ████████ <b>SSN:</b> ████████ <b>Client:</b>																																																													

Ordering Provider	Collect Date & Time	Date of Service	Status Change Date	Status	Signed	Req. Number	
ROETHLE, S	4/1/2021 8:51 am	4/1/2021 12:00 am	4/20/2021 8:07pm	FINAL	04/21/2021 PEYTON	B0113848486	
Diagnostic Test / Results	Results	Out of Range	Flag	Units	Range	Site	Stat
<b>Luteinizing Hormone(LH), S [Final]</b>							
LH	6.5			mIU/mL	1.7-8.6	01	F
<b>Prostate-Specific Ag, Serum [Final]</b>							
Prostate Specific Ag, Serum	0.6			ng/mL	0.0-4.0	01	F
Notes	<p>Roche ECLIA methodology.</p> <p>According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.</p> <p>Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.</p>						
<b>IGF-1 [Final]</b>							
Insulin-Like Growth Factor I	150			ng/mL	81-263	02	F
<b>Estradiol, Sensitive [Final]</b>							
Estradiol, Sensitive	22.6			pg/mL	8.0-35.0	02	F
Notes	<p>This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration.</p> <p>Methodology: Liquid chromatography tandem mass spectrometry(LC/MS/MS)</p>						
<b>Sex Horm Binding Glob, Serum [Final]</b>							
Sex Horm Binding Glob, Serum	51.2			nmol/L	16.5-55.9	01	F
<b>Cardiovascular Report [Final]</b>							
Interpretation	Note					03	F
Notes	Supplemental report is available.						
PDF						03	F
<b>Tests Performed at Labs / Sites</b>							
01	LabCorp Seattle 550 17th Avenue Ste 300 Seattle, WA 981225789 - Towell L Daniel, MD - 2068617000						
02	LabCorp Spokane 110 W Cliff Dr. Ste 100-200 Spokane, WA 992043614 - LaPointe R Jennifer, MD - 8003498586						
03	LabCorp Burlington 1447 York Court Burlington, NC 272153361 - Nagendra Sanjai, MD - 8007624344						
<b>Flag Legend:</b> Flag Legend: L (Below Low Normal) H (Above High Normal) LL (Alert Low) HH (Alert High) < (Panic Low) > (Panic High) A (Abnormal) AA (Critical Abnormal)							
Lab Patient Name:		DOB:		SSN:		Client:	